Walvax Biotechnology Statistics
Total Valuation
Walvax Biotechnology has a market cap or net worth of CNY 23.83 billion. The enterprise value is 23.38 billion.
Market Cap | 23.83B |
Enterprise Value | 23.38B |
Important Dates
The next estimated earnings date is Friday, October 25, 2024.
Earnings Date | Oct 25, 2024 |
Ex-Dividend Date | May 30, 2024 |
Share Statistics
Walvax Biotechnology has 1.60 billion shares outstanding. The number of shares has decreased by -0.17% in one year.
Shares Outstanding | 1.60B |
Shares Change (YoY) | -0.17% |
Shares Change (QoQ) | -0.67% |
Owned by Insiders (%) | 9.29% |
Owned by Institutions (%) | 15.76% |
Float | 1.38B |
Valuation Ratios
The trailing PE ratio is 176.95 and the forward PE ratio is 46.56.
PE Ratio | 176.95 |
Forward PE | 46.56 |
PS Ratio | 7.05 |
PB Ratio | 2.51 |
P/FCF Ratio | 454.24 |
PEG Ratio | n/a |
Enterprise Valuation
The stock's EV/EBITDA ratio is 41.19, with an EV/FCF ratio of 445.62.
EV / Earnings | 173.54 |
EV / Sales | 6.92 |
EV / EBITDA | 41.19 |
EV / EBIT | 102.44 |
EV / FCF | 445.62 |
Financial Position
The company has a current ratio of 2.94, with a Debt / Equity ratio of 0.06.
Current Ratio | 2.94 |
Quick Ratio | 2.52 |
Debt / Equity | 0.06 |
Debt / EBITDA | 1.32 |
Debt / FCF | 14.28 |
Interest Coverage | 23.83 |
Financial Efficiency
Return on equity (ROE) is 1.79% and return on invested capital (ROIC) is 1.17%.
Return on Equity (ROE) | 1.79% |
Return on Assets (ROA) | 0.93% |
Return on Capital (ROIC) | 1.17% |
Revenue Per Employee | 1.42M |
Profits Per Employee | 56,412 |
Employee Count | 2,388 |
Asset Turnover | 0.22 |
Inventory Turnover | 0.77 |
Taxes
Income Tax | n/a |
Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has decreased by -27.77% in the last 52 weeks. The beta is 0.72, so Walvax Biotechnology's price volatility has been lower than the market average.
Beta (5Y) | 0.72 |
52-Week Price Change | -27.77% |
50-Day Moving Average | 11.29 |
200-Day Moving Average | 14.95 |
Relative Strength Index (RSI) | 64.57 |
Average Volume (20 Days) | 39,981,180 |
Short Selling Information
Short Interest | n/a |
Short Previous Month | n/a |
Short % of Shares Out | n/a |
Short % of Float | n/a |
Short Ratio (days to cover) | n/a |
Income Statement
In the last 12 months, Walvax Biotechnology had revenue of CNY 3.38 billion and earned 134.71 million in profits. Earnings per share was 0.08.
Revenue | 3.38B |
Gross Profit | 2.55B |
Operating Income | 228.22M |
Pretax Income | 248.65M |
Net Income | 134.71M |
EBITDA | 541.40M |
EBIT | 228.22M |
Earnings Per Share (EPS) | 0.08 |
Balance Sheet
The company has 3.33 billion in cash and 749.32 million in debt, giving a net cash position of 2.59 billion or 1.62 per share.
Cash & Cash Equivalents | 3.33B |
Total Debt | 749.32M |
Net Cash | 2.59B |
Net Cash Per Share | 1.62 |
Equity (Book Value) | 11.64B |
Book Value Per Share | 5.94 |
Working Capital | 4.94B |
Cash Flow
In the last 12 months, operating cash flow was 838.70 million and capital expenditures -786.24 million, giving a free cash flow of 52.46 million.
Operating Cash Flow | 838.70M |
Capital Expenditures | -786.24M |
Free Cash Flow | 52.46M |
FCF Per Share | 0.03 |
Margins
Gross margin is 75.50%, with operating and profit margins of 6.75% and 3.99%.
Gross Margin | 75.50% |
Operating Margin | 6.75% |
Pretax Margin | 7.36% |
Profit Margin | 3.99% |
EBITDA Margin | 16.02% |
EBIT Margin | 6.75% |
FCF Margin | 1.55% |
Dividends & Yields
This stock pays an annual dividend of 0.01, which amounts to a dividend yield of 0.06%.
Dividend Per Share | 0.01 |
Dividend Yield | 0.06% |
Dividend Growth (YoY) | n/a |
Years of Dividend Growth | n/a |
Payout Ratio | 17.76% |
Buyback Yield | 0.17% |
Shareholder Yield | 0.23% |
Earnings Yield | 0.57% |
FCF Yield | 0.22% |
Stock Splits
The last stock split was on October 14, 2015. It was a forward split with a ratio of 3.
Last Split Date | Oct 14, 2015 |
Split Type | Forward |
Split Ratio | 3 |
Scores
Walvax Biotechnology has an Altman Z-Score of 6.62.
Altman Z-Score | 6.62 |
Piotroski F-Score | n/a |